AGN up +0.41% percent Today $AGN High is at 198.58 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 12:35 PM

AGN up +0.41% percent Today $AGN High is at 198.58 and the Low 195.06 with current volume of 295,234.

Recent News posted below.

Allergan Inc AGN other info.
http://investorshangout.com/Allergan-AGN-50031/

AGN Allergan Inc Recent Headline News

Physicians Continue to Voice Strong Support for Allergan via Open Letters to the Eye Care Community
Business Wire - Fri Nov 14, 8:00AM CST
Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company"

today announced results from a recent survey of eye care professionals and the availability of an open letter website in response to requests from physician customers for a platform to voice their concerns regarding the unsolicited proposal from Valeant Pharmaceuticals International, Inc. ("Valeant"

to acquire Allergan.
AGN: 197.37 (+1.16), VRX.TO: 150.12 (-0.03)

Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - Fri Nov 14, 7:30AM CST

ZTS: 43.09 (-0.15), AGN: 197.37 (+1.16), VRX: 133.02 (+1.12), ACT: 244.74 (+3.11)

Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 43.09 (-0.15), AGN: 197.37 (+1.16), ACT: 244.74 (+3.11), VRX: 133.02 (+1.12)

Allergan Has Returned 18.0% Since SmarTrend Recommendation (AGN)
Comtex SmarTrend(R) - Thu Nov 13, 11:14AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 17.97% as of today's recent price of $197.14.
AGN: 197.37 (+1.16)

Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 197.37 (+1.16), VRX: 133.02 (+1.12), ACT: 244.74 (+3.11)

Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 197.37 (+1.16), JNJ: 108.29 (-0.78), GILD: 101.76 (-2.44), ABBV: 63.46 (-0.17)

FDA Approves New Styles of Allergan's NATRELLE(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
Business Wire - Wed Nov 12, 3:50PM CST
Allergan, Inc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market two new styles, X and L, of the Natrelle(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery.
AGN: 197.37 (+1.16)

Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 43.09 (-0.15), AGN: 197.37 (+1.16), VRX: 133.02 (+1.12), ACT: 244.74 (+3.11)

Actavis closing in on Allergan
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:22AM CST

AGN: 197.37 (+1.16), ACT: 244.74 (+3.11)

Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 197.37 (+1.16), ABBV: 63.45 (-0.18), SNY: 46.56 (+0.03), REGN: 394.62 (-8.01)

Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.09 (-0.15), AGN: 197.37 (+1.16), HLF: 37.64 (-0.21), VRX: 133.02 (+1.12), PFE: 30.23 (-0.19), MRK: 58.80 (-0.74), LLY: 67.21 (-0.47)

5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.75 (unch), AGN: 197.37 (+1.16), ACT: 244.76 (+3.13), IRWD: 13.06 (-0.43), CBST: 69.77 (-1.97), PFE: 30.23 (-0.19)

Allergan tweaks bylaws pertaining to special meeting requests
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:07AM CST

AGN: 197.37 (+1.16), VRX: 133.02 (+1.12)

Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST

WDFC: 76.91 (-0.42), SJR: 26.49 (+0.08), PRGO: 153.79 (-1.74), XYL: 37.40 (-0.05), CHRW: 73.41 (+0.30), MDLZ: 38.33 (+0.10), MKC: 72.88 (-0.38), MDU: 25.11 (+0.11), SYY: 38.68 (-0.06), PDCO: 45.17 (-0.53), PNR: 68.61 (+0.14), TRI: 38.16 (+0.08), UPS: 107.06 (-0.73), PEP: 97.97 (-0.57), AGN: 197.37 (+1.16), MSI: 64.89 (+0.46), NOV: 71.02 (-0.50), NWN: 46.60 (-0.12), EGN: 67.62 (+0.66), EBAY: 54.24 (-0.13), QCOM: 70.77 (+0.12), AMAT: 22.89 (+0.27), ACN: 84.55 (+0.11), AAPL: 113.96 (+1.14), MA: 84.15 (-0.05), SCHW: 28.88 (+0.09), STR: 23.49 (-0.27), SE: 37.86 (unch), GAS: 51.59 (-0.06), IRM: 37.99 (-0.38), WM: 49.12 (-0.25), CMP: 88.64 (+0.27), VRSK: 63.12 (-0.04), GILD: 101.77 (-2.43), EXPD: 43.95 (+0.05), TFX: 115.05 (+0.41), CVS: 89.38 (-0.75), PG: 88.37 (-0.23), PX: 126.06 (-0.67), NVS: 93.98 (-0.40)

Allergan Board of Directors Announces Approval of Amendments to Company's Bylaws
Business Wire - Wed Nov 12, 6:01AM CST
--Amendments Follow Meetings with Major Stockholders to Solicit Their Perspectives
AGN: 197.37 (+1.16)

Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.37 (+1.16), GILD: 101.77 (-2.43), ABBV: 63.45 (-0.18), BMY: 57.64 (-0.16)

Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 197.37 (+1.16), VRX: 133.02 (+1.12), ACT: 244.76 (+3.13)

Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 106.27 (-0.94), AGN: 197.37 (+1.16), JNJ: 108.30 (-0.77), DNDN: 0.12 (-0.01)

Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST

AGN: 197.37 (+1.16), ZTS: 43.09 (-0.15), ACT: 244.76 (+3.13), VRX: 133.02 (+1.12)

Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.75 (unch), AGN: 197.37 (+1.16), ACT: 244.76 (+3.13), VRX: 133.02 (+1.12), MDT: 68.88 (-0.50), SLXP: 98.84 (+1.85), SNY: 46.56 (+0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Digital Wine Atlas Maps 4.3 Million Vineyards Globally

Revolutionizing Viticulture with Data In today's wild world, climate change isn't just shifting weather patterns—it's upending the age-old map of wine-making regions. We've got a new player on the field: the World Winery Map. It's digital, massive, and it’s shaking things up for winemakers and grape enthusiasts alike. This platform covers a staggering 4.3 million...

DAHON's Tech: Crafting Folders That Ride Like Road Bikes

The Folding Bike Revolution: More Than Just a Fad You've seen them zipping around—those compact, folding bikes. They're not just for urban commuters looking to save space. Oh no, this is a full-blown cycling revolution we're talking about. DAHON, a name that's been rolling since 1982, has been riding these waves and making strides that others can only dream of. While...

FOSSI Opens 2027 Applications for Future STEM Leaders

Paving Pathways in the Chemical Industry There's something brewing that's got me eyeing the future with cautious optimism, and it doesn't involve hedge funds or earnings reports. It's the Future of STEM Scholars Initiative (FOSSI) playing its cards just right, planting seeds for tomorrow's innovators. This puppy opened the gates for 2027 applications, and for young brains...

AI Ambassadors Rethink Arbitration's Future

Navigating the AI Terrain in Arbitration It's 2026 and artificial intelligence isn't just a buzzword anymore; it's reshaping every corner of how disputes get resolved. The American Arbitration Association (AAA) has jumped into the mix, launching an AI Ambassador program to tackle a wave of AI-induced challenges. These aren't just academic exercises—this is a hard-nosed...

Mental Health Day Celebrations Set for October in NYC

Mental Health Steals the October Spotlight In the bustling streets of New York City, October is about to get a mental health makeover. Project Healthy Minds is putting the pedal to the metal with their fourth annual World Mental Health Day Gala on October 8th, followed by the world’s largest mental health festival on October 10th. These events, held at Spring Studios,...

California Accelerates AI Law with Newsom's Bold Move

Pushing AI Regulations into High Gear I'll tell you what—it's about time somebody shook things up in the AI world with more than empty promises. Governor Newsom's executive order is doing just that, fast-tracking the timeline for implementing California's SB 813. This move is like giving speed boots to the legislative process, revving up the rules to ensure AI doesn't...

Crimson Coward's Cheez Nugs Shake Up Fast-Casual Scene

New Kid on the Block: Cheez Nugs Buckle up folks, Crimson Coward is at it again. They're rolling out something they claim will blow your taste buds straight out of the water: Cheez Nugs. Dropping nationwide on September 18, 2026, these aren't your run-of-the-mill cheese bites. We're talking 100% whole-milk mozzarella, a golden herb-seasoned crust, and a mouthful of creamy...

Kobold Press Explores Roleplaying as Literacy Tool

Gaming Illuminates Pathways to Literacy and Community Trust me, when an indie game publisher like Kobold Press makes waves, it's worth paying attention. They've carved a niche in the roleplaying world by marrying traditional game elements with valuable educational tools. The thrill of the game goes beyond rolling dice; it's a ticket to improving literacy, arithmetic, and...

Arizona Voters Demand Clear Plans for 2026 Election

A Shift in Voter Expectations: Clear Actions Needed Arizona voters have spoken, and they aren't looking for the same old political song and dance anymore. They crave something meatier—action, not just words. Heading into the 2026 general election, folks in the Grand Canyon State are demanding concrete solutions and straightforward answers from those who seek to lead...

IRS Views Challenge Tax-Engineered Healthcare Schemes

Nonprofit Models Shine Amid IRS Scrutiny Out in Oxnard, California, there's a brewing storm in the healthcare sector. No, it's not a billing error or yet another scandal. We're talking about a seismic shift that could poke holes in those tax-engineered Section 105(b) programs, all thanks to some hard-hitting IRS memoranda. The Nonprofit–TPA Model: A Safer Bet? Enter...